|
Market Closed -
Toronto S.E.
20:58:18 16/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 4.880 CAD | -8.96% |
|
-13.01% | -50.20% |
Company Valuation: BriaCell Therapeutics Corp.
Data adjusted to current consolidation scope
| Fiscal Period: July | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 5.148 | 78.61 | 101.5 | 106.4 | 13.63 | 12.81 |
| Change | - | 1,427.04% | 29.07% | 4.9% | -87.19% | -6.05% |
| Enterprise Value (EV) 1 | 5.429 | 21.37 | 60.42 | 85.18 | 12.77 | -5.058 |
| Change | - | 293.6% | 182.77% | 40.98% | -85.01% | -139.6% |
| P/E | - | -54.3x | -3.77x | -5.12x | -2.56x | -0.12x |
| PBR | - | 1.37x | 9.82x | -28.2x | -5.72x | 0.77x |
| PEG | - | - | -0x | 0.2x | 0x | -0x |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -1.13x | -3.07x | -3.96x | -3.66x | -0.38x | 0.19x |
| EV / EBIT | -1.12x | -3.06x | -3.95x | -3.66x | -0.38x | 0.19x |
| EV / FCF | 21x | -3.65x | -8.81x | -5.37x | -1.18x | 0.27x |
| FCF Yield | 4.77% | -27.4% | -11.3% | -18.6% | -84.8% | 374% |
| Dividend per Share 3 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 3 | - | -14.22 | -259.8 | -195 | -43.68 | -62.19 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -4.821 | -6.958 | -15.27 | -23.26 | -33.25 | -27.1 |
| EBIT 1 | -4.84 | -6.973 | -15.29 | -23.27 | -33.33 | -27.2 |
| Net income 1 | -4.944 | -0.4283 | -26.84 | -20.3 | -4.791 | -26.31 |
| Net Debt 1 | 0.2808 | -57.24 | -41.04 | -21.25 | -0.8621 | -17.87 |
| Reference price 3 | 1,069.572 | 772.222 | 980.759 | 998.928 | 111.849 | 7.298 |
| Nbr of stocks (in thousands) | 4.81 | 102 | 103 | 107 | 122 | 1,755 |
| Announcement Date | 30/11/20 | 28/10/21 | 27/10/22 | 25/10/23 | 29/10/24 | 15/10/25 |
1USD in Million2CAD in Million3USD
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 30.01M | |
| 18.75x | 6.69x | 13.41x | 1.58% | 65B | |
| 27.56x | 7.53x | 23.83x | 0.05% | 51.19B | |
| 35.3x | 6.27x | 18.74x | 0.92% | 51.2B | |
| 34.01x | 3.32x | 14.33x | -.--% | 43.93B | |
| 48.9x | 5.59x | 30.73x | -.--% | 41.96B | |
| -18.47x | 189.62x | -19.51x | -.--% | 38.14B | |
| 28.97x | 8.21x | 21.25x | 0.37% | 33.24B | |
| 29.19x | 6.17x | 16.01x | -.--% | 25.2B | |
| -13.23x | 4.78x | -5.79x | -.--% | 22.03B | |
| Average | 21.22x | 26.46x | 12.55x | 0.32% | 37.19B | |
| Weighted average by Cap. | 23.35x | 24.98x | 14.00x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- BCT Stock
- Valuation BriaCell Therapeutics Corp.
Select your edition
All financial news and data tailored to specific country editions
